NO20045517L - Ny kombinasjon - Google Patents

Ny kombinasjon

Info

Publication number: NO20045517L
Authority: NO; Norway
Prior art keywords: inhibitor; new combination; aee; pde5; cgmp
Prior art date: 2002-05-23

Application number

NO20045517A

Other languages

English (en)

Norwegian (no)

Inventor

David Nathan Abraham Fox

Bernadette Hughes

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-23

Filing date

2004-12-17

Publication date

2004-12-17

2002-05-23 Priority claimed from GB0211919A external-priority patent/GB0211919D0/en

2002-12-20 Priority claimed from GB0229784A external-priority patent/GB0229784D0/en

2004-12-17 Application filed by Pfizer filed Critical Pfizer

2004-12-17 Publication of NO20045517L publication Critical patent/NO20045517L/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20045517A 2002-05-23 2004-12-17 Ny kombinasjon NO20045517L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0211919A GB0211919D0 (en)	2002-05-23	2002-05-23	Novel combination
GB0229784A GB0229784D0 (en)	2002-12-20	2002-12-20	Novel combination
PCT/IB2003/001889 WO2003099194A2 (fr)	2002-05-23	2003-05-09	Nouvelle combinaison

Publications (1)

Publication Number	Publication Date
NO20045517L true NO20045517L (no)	2004-12-17

Family

ID=29585817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045517A NO20045517L (no)	2002-05-23	2004-12-17	Ny kombinasjon

Country Status (18)

Country	Link
EP (1)	EP1506015A2 (fr)
JP (1)	JP2005529927A (fr)
KR (1)	KR20050004195A (fr)
CN (1)	CN1655820A (fr)
AR (1)	AR040090A1 (fr)
AU (1)	AU2003223071A1 (fr)
BR (1)	BR0311191A (fr)
CA (1)	CA2485984A1 (fr)
IL (1)	IL164975A0 (fr)
MX (1)	MXPA04010951A (fr)
NO (1)	NO20045517L (fr)
PA (1)	PA8574201A1 (fr)
PE (1)	PE20040514A1 (fr)
PL (1)	PL374198A1 (fr)
RU (1)	RU2004133973A (fr)
TW (1)	TW200407153A (fr)
UY (1)	UY27816A1 (fr)
WO (1)	WO2003099194A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7019010B2 (en)	2001-09-27	2006-03-28	Novertis Ag	Combinations
GB0318094D0 (en) *	2003-08-01	2003-09-03	Pfizer Ltd	Novel combination
DE102004011512B4 (de)	2004-03-08	2022-01-13	Boehringer Ingelheim Vetmedica Gmbh	Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (fr)	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
US8980894B2 (en)	2004-03-25	2015-03-17	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (fr) *	2006-06-13	2012-12-07	Bioprojet Soc Civ	Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
ES2548759T3 (es)	2006-08-24	2015-10-20	Surface Logix, Inc.	Compuestos farmacocinéticamente mejorados
EP1920785A1 (fr)	2006-11-07	2008-05-14	Boehringer Ingelheim Vetmedica Gmbh	Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
HUE060093T2 (hu)	2012-03-15	2023-01-28	Boehringer Ingelheim Vetmedica Gmbh	Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
HUE054186T2 (hu)	2013-07-19	2021-08-30	Boehringer Ingelheim Vetmedica Gmbh	Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
ES2883448T3 (es)	2013-12-04	2021-12-07	Boehringer Ingelheim Vetmedica Gmbh	Composiciones farmacéuticas mejoradas de pimobendán
US10537570B2 (en)	2016-04-06	2020-01-21	Boehringer Ingelheim Vetmedica Gmbh	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4316906A (en) *	1978-08-11	1982-02-23	E. R. Squibb & Sons, Inc.	Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
CA2395558C (fr) *	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
HK1049834A1 (zh) *	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en) *	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

2003
- 2003-05-09 CA CA002485984A patent/CA2485984A1/fr not_active Abandoned
- 2003-05-09 RU RU2004133973/15A patent/RU2004133973A/ru not_active Application Discontinuation
- 2003-05-09 JP JP2004506721A patent/JP2005529927A/ja not_active Abandoned
- 2003-05-09 PL PL03374198A patent/PL374198A1/xx not_active Application Discontinuation
- 2003-05-09 KR KR10-2004-7018868A patent/KR20050004195A/ko not_active Abandoned
- 2003-05-09 AU AU2003223071A patent/AU2003223071A1/en not_active Abandoned
- 2003-05-09 CN CNA038118262A patent/CN1655820A/zh active Pending
- 2003-05-09 BR BR0311191-1A patent/BR0311191A/pt not_active IP Right Cessation
- 2003-05-09 WO PCT/IB2003/001889 patent/WO2003099194A2/fr not_active Ceased
- 2003-05-09 MX MXPA04010951A patent/MXPA04010951A/es unknown
- 2003-05-09 EP EP03719042A patent/EP1506015A2/fr not_active Withdrawn
- 2003-05-12 TW TW092112826A patent/TW200407153A/zh unknown
- 2003-05-19 PE PE2003000482A patent/PE20040514A1/es not_active Application Discontinuation
- 2003-05-21 AR ARP030101762A patent/AR040090A1/es unknown
- 2003-05-21 UY UY27816A patent/UY27816A1/es not_active Application Discontinuation
- 2003-05-22 PA PA20038574201A patent/PA8574201A1/es unknown
2004
- 2004-11-01 IL IL16497504A patent/IL164975A0/xx unknown
- 2004-12-17 NO NO20045517A patent/NO20045517L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR040090A1 (es)	2005-03-16
CA2485984A1 (fr)	2003-12-04
PL374198A1 (en)	2005-10-03
AU2003223071A1 (en)	2003-12-12
IL164975A0 (en)	2005-12-18
BR0311191A (pt)	2005-03-01
PA8574201A1 (es)	2003-12-19
EP1506015A2 (fr)	2005-02-16
JP2005529927A (ja)	2005-10-06
RU2004133973A (ru)	2005-09-10
MXPA04010951A (es)	2005-06-08
TW200407153A (en)	2004-05-16
WO2003099194A3 (fr)	2004-06-03
WO2003099194A2 (fr)	2003-12-04
UY27816A1 (es)	2003-12-31
KR20050004195A (ko)	2005-01-12
PE20040514A1 (es)	2004-08-24
CN1655820A (zh)	2005-08-17

Legal Events

Date	Code	Title	Description
2008-01-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20045517L (no)	2004-12-17	Ny kombinasjon
HN2003000227A (es)	2005-10-20	Inhibidores de quinasas
NO20053115L (no)	2005-08-18	Fremgangsmate for fremstilling av 2'-forgrenede nukleosider.
CY1105390T1 (el)	2010-04-28	Θepαπευτικη αγωγη της πνευμονικης υπερτασης
DE60309848D1 (de)	2007-01-04	Purinderivate als kinaseinhibitoren
EA200700488A1 (ru)	2007-08-31	S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ КАК ИНГИБИТОРЫ ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ
NO20052887D0 (no)	2005-06-14	Pyridazinonderivater som GSK-3Beta inhibitorer.
EA201000491A1 (ru)	2010-08-30	Аминометилзамещенные тетрациклиновые соединения
HUP0104131A2 (hu)	2002-03-28	Aminnal reakcióra képes egy vagy több aktív összetevőt tartalmazó készítmények
SE0203752D0 (sv)	2002-12-17	New compounds
ATE414699T1 (de)	2008-12-15	Inhibitoren von tyrosinkinasen
EA200501928A1 (ru)	2006-12-29	Пирролодигидроизохинолины как ингибиторы pde10
DE69811645D1 (de)	2003-04-03	Phtalazinonen
MXPA05006629A (es)	2005-09-30	Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
MXPA04011951A (es)	2005-03-31	Inhibidores de peptido desformilasa.
DE602004009824D1 (de)	2007-12-13	Analyse von massenspektraldaten in den ruhigen gebieten
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20050400L (no)	2005-03-29	Nytt kombinasjonspreparat
EP1513402A4 (fr)	2009-10-28	Inhibiteurs ameliores d'adp-ribosyl transferases, cyclases, et hydrolases
EP1570847A4 (fr)	2008-10-08	Inhibiteurs de phosphodiesterase 10a
GB0205910D0 (en)	2002-04-24	Arrays and methods
SE0302361D0 (sv)	2003-09-03	Inhibering av upptagning av monoamin
TW200509911A (en)	2005-03-16	Novel combination
DE60307997D1 (de)	2006-10-12	Zusammensetzungen mit biostimulierender wirksamkeit
NO20042684L (no)	2004-06-25	Benzotia(dia)zinderivater og deres anvendelse som ampa-modulatorer